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INTRODUCTION
Gliomas are the most common primary parenchymal 
brain tumors in the United States [1]. They are histologically 
diagnosed as the third most common primary tumor of the 
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Background    There was no practical guideline for the management of patients with central nervous 
system tumor in Korea for many years. Thus, the Korean Society for Neuro-Oncology (KSNO), a multi-
disciplinary academic society, has developed the guideline for glioblastoma. Subsequently, the KSNO 
guideline for World Health Organization (WHO) grade II cerebral glioma in adults is established.
Methods    The Working Group was composed of 35 multidisciplinary medical experts in Korea. 
References were identified by searching PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL da-
tabases using specific and sensitive keywords as well as combinations of keywords regarding diffuse 
astrocytoma and oligodendroglioma of brain in adults. 
Results    Whenever radiological feature suggests lower grade glioma, the maximal safe resection 
if feasible is recommended globally. After molecular and histological examinations, patients with diffuse as-
trocytoma, isocitrate dehydrogenase (IDH)-wildtype without molecular feature of glioblastoma should be 
primarily treated by standard brain radiotherapy and adjuvant temozolomide chemotherapy (Level III) while 
those with molecular feature of glioblastoma should be treated following the protocol for glioblastomas. In 
terms of patients with diffuse astrocytoma, IDH-mutant and oligodendroglioma (IDH-mutant and 1p19q 
codeletion), standard brain radiotherapy and adjuvant PCV (procarbazine+lomustine+vincristine) combina-
tion chemotherapy should be considered primarily for the high-risk group while observation with regular 
follow up should be considered for the low-risk group.
Conclusion    The KSNO’s guideline recommends that WHO grade II gliomas should be treated by 
maximal safe resection, if feasible, followed by radiotherapy and/or chemotherapy according to molec-
ular and histological features of tumors and clinical characteristics of patients.
Key Words  Korean Society for Neuro-Oncology; Guideline; Grade II Gliomas; Practice. 
central nervous system (CNS) in a relatively small portion in 
Korea [2]. According to the World Health Organization 
(WHO) classification of CNS tumors, the following tumors 
are classified as WHO grade II gliomas: diffuse astrocytoma, 
oligodendroglioma, pilomyxoid astrocytoma, pleomorphic 
xanthoastrocytoma, and ependymoma [3]. In fact, WHO 
grade II and III gliomas are not as common as glioblastomas. 
Other malignant gliomas including WHO grade II and III 
gliomas account for 10.2% and 5.3% of all primary CNS tu-
mors in the United State [1] and Korea [2], respectively. 
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The updated 4th edition of the WHO classification of CNS 
tumors was published in 2016. It had substantial changes com-
pared to the previous edition of classification published in 2007. 
One of the most significant changes was the inclusion of both 
morphology and molecular features to have an integrated diag-
nosis for specific tumor entities [3,4]. In terms of diagnosis of 
glioma, there are several discrepancies in histological classifica-
tion of gliomas due to considerable interobserver variability [5]. 
Recently, many studies using next-generation sequencing and 
microarray-based analyses have revealed characteristic genetic 
and epigenetic profiles of various types of gliomas [6]. Molecu-
lar biomarkers that may refine tumor diagnostics and improve 
prediction of treatment response and outcome have been iden-
tified [7]. These advancements in precise diagnoses are driven 
by widely available techniques such as immunohistochemistry, 
fluorescence in-situ hybridization (FISH), and DNA sequenc-
ing, and they make it possible to examine important molecular 
biomarkers for use with routinely formalin-fixed and paraffin-
embedded (FFPE) materials [6]. 
This paradigm shift was foreshadowed by the Haarlem rec-
ommendation that endorsed the incorporation of molecular 
biomarkers into pathologic diagnoses [4,8]. Major shifts in 
pathologic diagnosis of WHO grade II glioma included the 
use of molecular definitions for isocitrate dehydrogenase 
(IDH)-mutant astrocytomas, oligodendroglioma (IDH-mu-
tant, 1p19q codeleted) and IDH-wildtype astrocytomas, re-
sulting in the elimination of oligoastrocytoma as an integrated 
diagnosis [3]. Additionally, the Consortium to Inform Molec-
ular and Practical Approaches to CNS Tumor Taxonomy 
(cIMPACT-NOW) was established to enhance understanding 
the molecular pathogenesis of brain tumor warranting more 
rapid integration of this information into clinical practice be-
tween WHO updates. The cIMPACT-NOW recommends 
that the following genetic studies are the minimal molecular 
criteria for identifying an IDH-wildtype diffuse astrocytic gli-
oma, although such IDH-wildtype diffuse astrocytic glioma 
appears histologically as a WHO grade II glioma known to 
have an aggressive clinical course and resemble IDH-wildtype 
glioblastoma: 1) epidermal growth factor receptor (EGFR) 
amplification, 2) combined whole chromosome 7 gain and 
whole chromosome 10 loss, and 3) telomerase reverse tran-
scriptase (TERT) promoter mutation [9]. 
In terms of clinical course and outcome, compared to 
WHO grade III or IV gliomas, WHO grade II glioma has 
relatively favorable clinical outcomes. Its 5-year progression-
free survival (PFS) and overall survival (OS) rates have been 
reported to be 52.2% and 83.0%, respectively, in Korea [10]. 
Its optimal primary treatment is surgical resection. Improved 
survival is expected after gross total resection [8]. Several 
clinical trials have examined effects of adjuvant radiotherapy 
including various dose escalation [11], optimal timing of ra-
diotherapy [12], and chemotherapy-combined radiotherapy 
[13] on WHO grade II glioma. Adjuvant chemotherapy has 
also been explored as a potential replacement of radiotherapy 
for WHO grade II glioma [14]. Although maximal surgical 
resection as the primary therapeutic modality for WHO 
grade II glioma is the general consensus, adequate adjuvant 
treatment strategies have not been established yet. 
Although the clinical practical guideline for grade IV glio-
mas has been developed and published recently by the Kore-
an Society for Neuro-Oncology (KSNO), a multidisciplinary 
academic society for CNS tumors [15], an actual guideline 
for the management of patients with other CNS tumors in 
Korea is not available yet. The KSNO established a Working 
Group for developing practice guideline for CNS tumor in 
February 2018. The working group is recently trying to de-
velop guidelines for CNS tumor based on updated informa-
tion. The objective of KSNO guideline for WHO grade II ce-
rebral gliomas is to provide physicians with evidence-based 
recommendations and consensus expert opinion for the 
management of patients with gliomas in daily clinical prac-
tice. It will also serve as a source of knowledge for institutions 
and insurance companies involved in cancer care in Korea.
KSNO GUIDELINE WORKING GROUP
A Working Group was appointed by the KSNO in February 
2018 to establish guidelines for the management of glioblasto-
ma patients. These guidelines should consider unique medical 
circumstance in Korea. The Working Group was composed of 
35 medical experts in Korea, including 18 neurosurgeons, 8 
radiation oncologists, 1 medical oncologist, 2 neuroradiolo-
gists, 3 pediatric oncologists, 2 pathologists, and 1 neurologist. 
As there is no medical specialty for neuro-oncology in Korea, 
neurosurgeon (especially brain tumor surgeon) usually plays a 
role of neuro-oncologist in clinical practice.
References were identified by searching PubMed, MED-
LINE, EMBASE, and Cochrane CENTRAL databases using 
specific and sensitive keywords as well as combinations of 
these keywords. Scope of the disease was confined to cerebral 
diffuse astrocytoma and oligodendroglioma in adults aged 
≥18 years because other grade II gliomas are relatively uncom-
mon in Korea. Therefore, grade II glioma in the spinal cord, 
pilomyxoid astrocytoma, ependymoma, and pleomorphic 
xanthoastrocytoma in the brain were excluded. Abstracts pre-
sented at official year-end conference of KSNO in December 
2018 were considered relevant. If available, existing guidelines 
from national multidisciplinary neuro-oncological societies 
such as the National Comprehensive Cancer Network 
(NCCN) and European Association of Neuro-Oncology 
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enhancement. Therefore, magnetic resonance image (MRI) 
with contrast enhancement is essential to diagnose a lower-
grade glioma. To obtain sufficient tissue for histopathological 
diagnosis, neurosurgical intervention is mandatory even if it is 
for stereotactic biopsy. To achieve maximal safe resection, neu-
ronavigation systems, intraoperative CT, MRI, intraoperative 
ultrasonography, intraoperative mapping techniques, and fluo-
rescence-guidance with 5-aminolevuliniv acid are recom-
mended. Histopathological diagnosis should be officially based 
on the 2016 WHO Classification of Tumors of the CNS [4].
Besides the importance of histopathological diagnosis of 
grade II glioma based on morphological features, codeletion 
of 1p19q testing and IDH1/2 mutation testing are also essen-
tial parts in the molecular diagnosis for grade II glioma. ATP-
dependent helicase (ATRX) mutation test is also required for 
workup of grade II gliomas. If the tumor has IDH-wildtype, 
the following molecular tests are strongly recommended: 1) 
EGFR amplification, 2) combined whole chromosome 7 gain 
and whole chromosome 10 loss, and 3) TERT promoter mu-
tation. MGMT promoter methylation test is also required for 
workup of all grade glioma.
ADJUVANT TREATMENT OF WHO 
GRADE II GLIOMAS
Diffuse astrocytoma, IDH-wildtype
In terms of histopathological and molecular features, dif-
fuse astrocytoma, IDH-wildtype should be additionally ana-
lyzed with molecular test to determine glioblastoma features. 
The tumor is considered to have molecular features of glio-
blastoma if it has one or more of the following findings: 1) 
(EANO) were also collected. The final reference list was gener-
ated based on originality and relevance to the scope of this 
guideline. The strategy of establishing this guideline was main-
ly based on NCCN and EANO guidelines with modifications 
and changes according to the unique background of Korea. 
Scientific evidence was assessed and graded according to 
the following categories: high level of evidence (evaluated 
from multiple populations and derived from randomized 
clinical trials or meta-analysis or systemic review) and low 
level of evidence (evaluated from limited population and de-
rived from non-randomized studies, including observational 
studies, cohort studies, and case-control studies).
To establish recommendation levels, the following criteria 
were used. Level I (strong recommendation) required a high 
level of evidence and uniform consensus among panels. Level 
II (weak recommendation) required a high level of evidence 
without uniform consensus among panels or low level of evi-
dence but uniform consensus among panels. Level III (indi-
vidual decision) required a low level of evidence without uni-
form consensus among panels. Level IV (not recommendable) 
required contents being not beneficial or harmful. Recom-
mendations with level I and level II evidence were not marked. 
However, those with level III and level IV evidence were 
marked at the end of each recommendation in this guideline.
DIAGNOSIS OF WHO GRADE II GLIOMAS
When the radiological feature suggests a lower-grade glioma, 
multidisciplinary approach for treatment planning should be 
considered if feasible (Fig. 1). Computed tomography (CT) is 
insufficient to suggest a lower-grade glioma even with contrast 
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Fig. 1. Guideline for diagnosis of WHO grade II glioma. To diagnose lower grade gliomas, MRI with gadolinium enhancement is essential 
even if the lesions do not have enhancement. A multidisciplinary approach for treatment planning is recommended if feasible. Primarily, 
WHO grade II gliomas should be diagnosed by based on both histopathological and molecular genetic features of the tissues obtained by 
neurosurgical intervention. KSNO, Korean Society for Neuro-Oncology; MRI, magnetic resonance image.
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EGFR amplification, 2) combined whole chromosome 7 gain 
and whole chromosome 10 loss, and 3) TERT promoter mu-
tation. If patients with diffuse astrocytoma, IDH-wildtype do 
not have molecular features of glioblastomas, they should be 
considered for the following modalities (Fig. 2): standard 
brain radiotherapy and adjuvant temozolomide chemothera-
py (Level III), standard brain radiotherapy alone, or observa-
tion. However, if patients with diffuse astrocytoma, IDH-
wildtype have molecular feature of glioblastomas, they should 
be treated following the protocol for glioblastomas (Fig. 2). 
The dose of temozolomide is recommended to be 150–200 
mg/m2 for 5 sequential days every 4 weeks (Level III).
Radiological follow-up using MRI with gadolinium en-
hancement is recommended for regular check-up at 2–6 weeks 
after radiotherapy, then every 6 months for 5 years, and then 
every 6–12 months until recurrence of the disease (Fig. 2). It is 
necessary to follow up regularly with shorter interval for dif-
fuse astrocytoma with IDH-wildtype than those with IDH-
mutant because IDH-wildtype has worse prognostic feature.
Diffuse astrocytoma, IDH-mutant and oligodendro-
glioma (IDH-mutant, 1p19q codeletion)
Patients who are older than 40 years and those who have 
not undergone gross total resection of the tumor are classi-
fied as the high-risk group. However, those who are younger 
than 40 years and those who have undergone gross total re-
section of the tumor are classified as the low-risk group. Al-
though other risk factors such as tumor size and neurological 
deficit are considered, this guideline does not consider these 
factors for deciding the therapeutic modality.
For patients in the high-risk group, the following adjuvant 
treatment should be considered primarily: standard brain ra-
diotherapy and adjuvant PCV (procarbazine, lomustine, and 
vincristine) combination chemotherapy, or concurrent 
chemoradiotherapy with temozolomide and adjuvant temo-
zolomide chemotherapy, or standard brain radiotherapy with 
adjuvant temozolomide chemotherapy (Fig. 3). For patients 
in the low-risk group, the following adjuvant treatment 
should be considered: observation and regular follow-up, or 
standard brain radiotherapy alone, or adjuvant PCV (procar-
bazine, lomustine, and vincristine) combination chemother-
apy alone (Fig. 3). The maximum number of cycles of adju-
vant chemotherapy using PCV regimen (procarbazine, 
lomustine, and vincristine) is 6. The recommended dose of 
temozolomide is 150–200 mg/m2 for 5 consequential days 
every 4 weeks for adjuvant purpose (Level III).
In terms of radiological follow-up, there is a uniform con-
sensus among the panel for routine check of MRI at 2–6 
weeks after radiotherapy with regular follow-up at 6–12 
months interval consequentially until recurrence including 
progression. It is necessary to follow up regularly at longer 
interval for diffuse astrocytoma with IDH-mutant than for 
diffuse astrocytoma with IDH-wildtype because IDH-mutant 
has better prognostic feature. 
TREATMENT OF RECURRENT WHO 
GRDE II GLIOMAS
It is more difficult to diagnose recurrences of WHO grade 
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WHO GRADE II GLIOMAS (2): ADJUVANT THERAPY (1)
MOLECULAR AND HISTOLOGIC FEATURES ADJUVANT TREATMENT
•Follow the protocol for the Glioblastomas
FOLLOW UP
Diffuse astrocytoma, IDH-wildtype
with molecular feature of Glioblastoma
Diffuse astrocytoma, IDH-wildtype
without molecular feature of Glioblastoma
•Standard brain radiotherapy and adjuvant
  temozolomide chemotherapy (Level III)
  or
•Standard brain rradiotherapy alone
  or
•Observation
Brain MRI
2–6 weeks after
radiotherapy 
then every, 
6 months
for 5 years,
then every 
6–12 months
until recurrence
Fig. 2. Guideline for adjuvant therapy of patients with diffuse astrocytoma, IDH-wildtype. 1) Patients with diffuse astrocytoma, IDH-wildtype 
without molecular feature of glioblastoma should be primarily treated by standard brain radiotherapy and adjuvant temozolomide chemo-
therapy (Level III), 2) while those with molecular feature of glioblastoma should be treated following the protocol for glioblastomas. IDH, iso-
citrate dehydrogenase; KSNO, Korean Society for Neuro-Oncology; MRI, magnetic resonance image.
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II gliomas than those of WHO grade III and IV gliomas be-
cause WHO grade II gliomas have less contrast enhancement. 
Especially, recurrence or progression can be indistinguishable 
from pseudoprogression on MRI within the first 3 months af-
ter completion of radiotherapy. However, the following radio-
logic findings can suggest recurrence or progression as rec-
ommended by radiologic assessment of neurooncology 
(RANO) criteria for low grade gliomas [16]: 1) 25% or more 
increase in the size of the lesion in fluid-attenuated inversion 
recovery (FLAIR) image and T2 weighted image, 2) any new 
lesion, and 3) clinical deterioration (not attributable to other 
non-tumor causes or steroid decrease) occurs simultaneously 
that strongly suggests true progression. 
If recurrence or progression is suspected based on the 
above criteria, it is better to consider the following options: 1) 
undergoing biopsy, 2) performing functional radiologic study 
such as MR spectroscopy, MR perfusion, brain positron emis-
sion tomography (PET)-CT, or 3) checking MRI again and 
comparing changes that might be due to progression versus 
other causes. When recurrence of the tumor is suggested clin-
ically and radiologically, surgical resection is always recom-
mended, if feasible (Fig. 4). Even if recurrence of WHO grade 
II glioma has difficulty to achieve complete resection due to 
diffuse, multi-focal, or deep located lesion, surgical treatment 
can be considered to reduce the mass effect and improve neu-
rological symptoms. The following systemic therapies can be 
considered for recurrent WHO grade II gliomas based on the 
physician’s decision: cytotoxic chemotherapy including re-
peated PCV, target therapy, and/or immunotherapy, and so 
on. Also, radiotherapy can be considered for patients naïve to 
radiotherapy. However, for patients who have undergone pri-
or radiotherapy, reirradiation can be considered, especially if 
the interval from prior radiotherapy is greater than 1 year, or 
if the new lesion is located outside the previously irradiated 
brain, or if the recurrence is small and geometrically favor-
able. Additionally, enrollment of clinical trials can be consid-
ered. Supportive treatment only can be considered for pa-
tients with poor performance status (Fig. 4).
PRINCIPLES OF THE MANAGEMENT 
OF WHO GRADE II GLIOMAS
Brain imaging
Many imaging modalities are available in neurooncology 
primarily to make treatment decisions in Korea. Imaging is 
always recommended to investigate emergent signs or symp-
toms. MRI of the brain (with and without contrast) is the gold 
standard modality to investigate brain tumors. It provides a 
static picture of brain tumors. It has a benefit in that it pro-
vides a reasonably good delineation of tumors. In MRI, high 
grade tumors and brain leptomeningeal metastases usually 
show enhancement while low-grade tumors usually do not. 
However, it has a limitation in that it is sensitive to movement. 
In addition, metallic objects can cause artifacts. Thus, patients 
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  adjuvant PCV chemotherapy
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Fig. 3. Guideline for adjuvant therapy of patients with diffuse astrocytoma, IDH-mutant and oligodendroglioma. 1) The standard brain radio-
therapy and adjuvant PCV (procarbazine+lomustine+vincristine) combination chemotherapy should be considered primarily for the high-risk 
group, 2) while observation with regular follow up should be considered for the low-risk group. IDH, isocitrate dehydrogenase; KSNO, Kore-
an Society for Neuro-Oncology; PCV, procarbazine+lomustine+vincristine; MRI, magnetic resonance image.
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with implantable devices cannot receive an MRI. Moreover, 
claustrophobia and renal insufficiency may be problematic. 
Postoperative brain MRI should be performed within 24–72 
hours after surgery for gliomas and other tumors to deter-
mine the extent of resection.
CT scan of the brain (with and without contrast) is usually 
considered for patients who cannot undergo an MRI. CT has a 
benefit of avoiding claustrophobia or implanted devices in the 
body. It is faster than an MRI. However, CT has a limitation in 
that it lacks resolution, especially for tumor located within the 
posterior fossa and for patients with renal insufficiency.
MR spectroscopy can be used to assess metabolites within 
tumor and normal tissues. It may be useful for differentiating 
tumors from radiation necrosis. It may also be helpful in 
grading tumors or assessing therapeutic response. The area 
showing the most abnormal features would be the best place 
for a biopsy. However, it has limitation for tumors near ves-
sels, air space, or bone. 
MR perfusion can be used to measure cerebral blood vol-
ume in tumors. It may be useful for differentiating the grade 
of tumor or tumor versus radiation necrosis. The area with 
the highest perfusion would be the best place for a biopsy. 
However, it has also limitation for tumors near vessels, air 
space, or bone, and small-volume lesions. 
PET-CT using fluorodeoxyglucose (FDG) has a limitation 
for functional diagnosis of WHO grade II cerebral glioma 
due to high uptake of FDG in the brain with normal biologic 
metabolism. However, PET-CT using methionine, an essen-
tial amino acid, may be helpful for differentiating the grade 
of tumor or tumor versus radiation necrosis. Unfortunately, 
this technology is not commonly used in the clinical field in 
Korea. Further development of its application is necessary 
for casual use in clinical practice.
Multidisciplinary care
During treatment, most patients with WHO grade II cere-
bral glioma will be managed by various subspecialists. Close 
and regular communication among all providers across 
multi-disciplines is essential. Utilization of a brain tumor 
board or multidisciplinary clinic care models can facilitate in-
teractions among various subspecialists. Ideally, allied health 
services (e.g., physical, occupational and speech therapies, 
nursing, psychology, and social services) should be included 
to optimize treatment plan recommendations. 
As treatment proceeds, it is important for patient and his/
her family to understand the role of each team member. One 
attending physician who mainly cares for the patient should 
be determined as early as possible and the attending physi-
cian should contact the patient regularly for follow up. Addi-
tionally, the attending physician should facilitate referral to 
appropriate specialist.
The patient is strongly encouraged to participate in various 
clinical trials. Practitioners should discuss local, regional, and 
national options for which patients may be eligible, along 
with advantages and disadvantages of their participation. The 
center that treats neuro-oncology patients should encourage 
patients to participate in large collaborative trials in order to 
have another option for patients.
Throughout treatment, patient’s health-related quality of 
life should remain the highest priority. It should guide clini-
cal decision-making. While therapeutic response in radio-
logic study is a good indicator of successful therapy, other 
non-radiologic indicators of therapeutic response such as 
overall well-being, cognitive function, physical and motor 
functioning in day-to-day activities, communication ability, 
social functioning and family interactions, nutrition, pain 
control, long-term consequences of treatment, and psycho-
logical issues should also be considered.
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WHO GRADE II GLIOMAS (3): RECURRENT DISEASE
RADIOLOGICAL FEATURES SALVAGE TREATMENT REFRACTORY
Supportive 
treatment
Recurrence of
Grade II Glioma
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if feasible
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•Consider radiotherapy, and/or
•Consider clinical trials and/or
•Supportive treatment if poor performance 
  status
Fig. 4. Guideline for recurrent WHO grade II gliomas. Surgical resection is always recommended, even in the recurrence of grade II glio-
mas with difficulty in complete resection such as diffuse, multi-focal, or deep located lesion in order to reduce the mass effect and improve 
the neurological symptoms. After surgical resection, the following therapeutic options are considered: 1) systemic chemotherapy, and/or 2) 
reirradiation, and/or 3) enrollment of clinical trials and/or 4) supportive treatment if poor performance status. KSNO, Korean Society for 
Neuro-Oncology.
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Patients should be informed of the possibility of pseudo-
progression. Its approximate incidence and potential investi-
gations may be needed if pseudoprogression is suspected. 
Close follow-up imaging, MR spectroscopy, PET-CT imag-
ing, and repeat neurosurgical intervention including biopsy 
and surgical resection may be necessary if clinically indicated.
Brain tumor surgery
General principles of surgical resection of WHO grade II 
cerebral glioma are as follows: gross total resection when ap-
propriate, minimal surgical morbidity, and accurate diagno-
sis. The following factors should be considered when deciding 
surgical resection: age, performance status, feasibility of de-
creasing the effect of mass with surgery, resectability, includ-
ing number of lesions, location of lesions, time since last sur-
gery in recurrent patients, new versus recurrent tumor, and 
timing of surgery in patient without symptoms [17]. Suspect-
ed pathology should also be considered with the following 
points: benign versus malignant, possibility of other non-can-
cer diagnoses, and projected natural history. For patients with 
IDH1 mutants, there is evidence suggesting that a supra-mar-
ginal resection is the most appropriate. It should include en-
hancing areas and T2/FLAIR areas when appropriate in terms 
of safe surgical approach, with the use of any or all surgical 
adjuncts possible [17].
Options of surgical resection include gross total resection 
where feasible, stereotactic biopsy, and open biopsy/debulk-
ing followed by planned observation or adjuvant therapy. To 
obtain the maximal safe resection, neuronavigation systems, 
intraoperative MRI or CT, intraoperative ultrasonography, 
fluorescence-guided surgery with 5-aminolevulinic acid, and 
intraoperative mapping techniques may be helpful. For his-
topathological diagnosis and genetic information, sufficient 
tissue should be sent to the pathologist for evaluating neuro-
pathological and molecular correlates. When possible, frozen 
section analysis can assist intraoperative decision making. 
The tissue should be reviewed by an experienced neuropa-
thologist.
Postoperative brain MRI should be performed within 24–72 
hours after surgery for WHO grade II cerebral glioma to de-
termine the extent of resection. The extent of resection should 
be judged based on postoperative imaging study. It should be 
used as a baseline to assess further therapeutic efficacy or tu-
mor progression.
Pathology examination
Incorporation of relevant diagnostic markers, including 
histopathologic and molecular information described in the 
2016 WHO Classification of Tumors of the CNS, should be 
considered as standard practice for tumor classification. Mo-
lecular/genetic characterization complements standard his-
tologic analysis, providing additional diagnostic and prog-
nostic information that can greatly improve diagnostic 
accuracy, influence treatment selection, and possibly improve 
management decision-making.
For standard histopathologic examination of WHO grade 
II cerebral gliomas, basic histologic examination is per-
formed based on description presented in the WHO Classifi-
cation of Tumors of the CNS [4]. Interobserver discrepancies 
in histologic diagnosis and grading are recognized issues due 
to the inherently subjective nature of certain aspects of histo-
pathologic interpretation (e.g., astrocytic vs. oligodendroglial 
morphology). In addition, surgical sampling does not always 
capture all relevant diagnostic features of morphologically 
heterogeneous tumors.
Through genetic and molecular testing, WHO grade II gli-
omas can be differentiated more accurately in terms of prog-
nosis and response to different therapies in some instances. 
However, molecular/genetic characterization does not re-
place standard histologic assessment. It serves as a comple-
mentary approach to provide additional diagnostic and 
prognostic information that can enhance treatment selec-
tion. Although there are no identified targeted agents with 
demonstrate efficacy in WHO grade II cerebral glioma, the 
panel encourages molecular testing of tumors such as per-
forming next generation sequencing because if a driver mu-
tation is detected, it may be reasonable to treat the patient 
with a targeted therapy on a compassionate use basis. In ad-
dition, the patient may have more treatment options in the 
context of a clinical trial.
Several specific molecular tests play a valuable role in im-
proving diagnostic accuracy and prognostic stratification 
that may inform treatment selection. IDH1 and IDH2 muta-
tion testing is an essential part for workup of WHO grade II 
glioma. If the tumor has IDH-wildtype, the following molec-
ular tests are strongly recommend: 1) EGFR amplification, 2) 
combined whole chromosome 7 gain and whole chromo-
some 10 loss, and 3) TERT promoter mutation. Codeletion 
of 1p19q testing is also an essential part of molecular diag-
nostics for oligodendrogliomas. Therefore, 1p19q codeletion 
testing should be considered to differentiate astrocytoma 
from oligodendrogliomas. ATRX mutation test and MGMT 
gene promoter methylation test are also helpful for workup 
of WHO grade II gliomas.
Radiotherapy
The optimal timing for radiotherapy after surgical resec-
tion has not been established yet in WHO grade II gliomas. 
No study has shown that delay in radiotherapy can decrease 
survival. However, if adjuvant radiotherapy is indicated for 
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patients, we recommend radiotherapy to be initiated at post-
operative 2–6 weeks after full patient recovery from surgical 
interventions. 
Whenever radiotherapy is planned for patients with WHO 
grade II gliomas, pre- and post-operative MRIs should be 
used to define all target volumes including gross and clinical 
tumor volume (GTV and CTV). Additional MRI at the time 
of radiotherapy simulation can be used to account for changes 
in surgical cavity or lesions. Planning CT-based 3-dimension-
al calculation of dose distribution should be used at any cir-
cumstance. The GTV should encompass preoperative tumor 
bed and high T2/FLAIR signals on postoperative MRI. Pre-
operative tumor bed should not be directly delineated on the 
registered preoperative MRI on the planning CT for patients 
undergoing surgical resection. An expansion of 1–2 cm CTV 
delineation to account for subclinical tumor infiltration 
should be utilized. Simple expansion from the GTV should 
be avoided. CTV should always be modified based on ana-
tomical barriers for tumor infiltration. A margin of 3–5 mm 
from the CTV is usually recommended to create planning 
target volume (PTV) to account for errors from image-regis-
tration and daily set-up of patients. However, the margin can 
also be reduced if daily image-guidance is performed.
A total dose of 45–54 Gy is recommended as standard ra-
diotherapy using a daily fraction of 1.8–2.0 Gy. Field reduc-
tion is not usually performed. Dose-escalation up to 60 Gy 
can be considered for IDH-wildtype WHO grade II gliomas 
considering their poor prognosis and aggressive nature. 
When intensity-modulated radiotherapy (IMRT) is used to 
avoid critical organs, simultaneous integrated boost (SIB) 
techniques can be used. Most patients with grade II glioma 
are usually considered for standard radiotherapy. However, 
in rare settings of fragile patients with old age or poor perfor-
mance, hypofractionated radiotherapy in 1–4 weeks can be 
considered. The following regimens can be used: 40.05 Gy/15 
fractions, 34 Gy/10 fractions, 50 Gy/20 fractions, and 25 
Gy/5 fractions. Of note, these regimens are adopted from the 
experience in high-grade gliomas and evidence supporting 
their use in low-grade gliomas is lacking. Absolute cumula-
tive dose limits and optimal interval between radiotherapy 
sessions for WHO grade II glioma remain unestablished. 
Delivery, dose, fraction, target volume, and techniques for 
reirradiation should be decided by brain tumor expert and 
radiation oncologist through multidisciplinary discussion 
whenever feasible.
DISCUSSION
This is the third practical guideline for CNS tumors which 
was developed by KSNO Guideline Working Group. Treat-
ment of newly diagnosed WHO grade II gliomas is more 
controversial than other gliomas in neurooncological fields 
due to heterogeneity of these tumors, their variability in nat-
ural history, concern regarding morbidity of treatment, and 
absence of proven overall survival benefit from any known 
treatment [18]. There is also still unresolved issue that in-
terobserver variation in distinction between WHO grades II 
and III is notoriously large, adding to the notion of a lack of 
relevance of WHO grading scale for individual glioma pa-
tients [18]. 
Historically, PCV chemotherapy is one of widely studied 
treatments for WHO grade II gliomas. Favorable responses 
seen with a combination of PCV in anaplastic oligodendrogli-
omas can lead to the evaluation of this combination in low 
grade oligodendrogliomas and oligoastrocytomas [19,20] and 
eventually all histologies of diffuse low grade gliomas, as in-
cluded in the Radiation Therapy Oncology Group (RTOG) 
9802. With this background, RTOG 9802 was designed with 
two cohorts: 1) a high-risk group randomized to adjuvant che-
motherapy or no adjuvant therapy after conventional radiation 
therapy; and 2) a low-risk group that was observed without ra-
diation or chemotherapy [21]. The high-risk group in this 
study was defined as patients with diffuse gliomas (regardless 
of histology) who were 40 years or older with any extent of re-
section and patients who were 18 years or older whose tumors 
were less than completely resected [21]. In initial results of 
RTOG 9802, with a median follow-up of 5.9 years, those treat-
ed with PCV chemotherapy were found to have significantly 
prolonged PFS compared to patients who were treated with 
radiation alone. However, OS was not significantly prolonged 
in prespecified initial analysis [21]. Finally, the mature results 
from long-term follow-up also demonstrated that the differ-
ence in OS between these two arms was statistically significant. 
Patients treated with radiation therapy and PCV had a median 
OS of 13.3 years compared to 7.8 years for radiation alone 
group [18]. Although lomustine is not commonly used for sol-
id cancer, it can be obtained by Korea Orphan and Essential 
drug Center. In addition, the Korean National Health Insur-
ance System covers the use of PCV regimen for patients with 
WHO grade II gliomas. 
The use of temozolomide is permitted for patients with 
WHO grade IV glioma and recurrent WHO grade III glioma 
in Korea, although it is still limited for those with WHO 
grade II gliomas. Over the past decade, PCV has been gradu-
ally replaced by temozolomide because temozolomide has an 
easier schedule and better tolerance by the patient. The 
RTOG 0424 trial, a phase II study of temozolomide-based 
chemoradiotherapy for high-risk low grade gliomas, showed 
that the 3-year OS rate of 73.1% for their cohort was higher 
than that reported for historical controls and the study-hy-
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pothesized rate of 65% [22]. In the trial, patients with high-
risk were treated with radiation therapy (54 Gy in 30 frac-
tions) and concurrent and adjuvant temozolomide. Up to 
date, several clinical trials have reported the effect of temo-
zolomide on low grade gliomas [10,14,22,23]. Therefore, this 
guideline recommends temozolomide chemotherapy for the 
newly diagnosed WHO grade II diffuse astrocytoma and 
high-risk oligodendrogliomas, even if this treatment is limit-
ed in Korea.
In this guideline, “high-risk” low grade gliomas patients 
are simply defined as those of younger than 40 years old and 
having undergone gross total resection of tumors. However, 
the “high-risk versus low-risk” classification has no means of 
representing the exact science. In the “low-risk” cohort of 
RTOG 9802, three prognostic factors predicted decreased 
PFS: 1) preoperative tumor diameter ≥4 cm; 2) astrocytoma 
or oligoastrocytoma histological subtype; and 3) residual tu-
mor ≥1 cm on MRI [20]. In the EORTC 22033 trial, at least 
one of the following criteria need to be present for classifica-
tion of “high-risk” low grade gliomas: 1) age ≥40 years, 2) 
radiologically proven progressive lesion, 3) new or worsen-
ing neurological symptoms other than seizures only (focal 
deficits, signs of raised intracranial pressure, mental deficits), 
or the presence of intractable seizures [14]. In the RTOG 
0424 trial, patients having 3 or more of the following risk fac-
tors for recurrence were classified as “high-preoperative 
risk”: 1) age ≥40 years, 2) astrocytoma histology, 3) bi-hemi-
spherical tumor, 4) tumor diameter of ≥6 cm, or a preopera-
tive neurological dysfunction [22]. A recent meta-analysis of 
four large randomized trials from the pre-molecular era (in-
cluding RTOG 9802) showed four factors related to worse 
OS: 1) the presence of baseline neurological deficits, 2) a 
shorter time since first symptoms (<30 weeks), 3) an astro-
cytic tumor type, and 4) tumors larger than 5 cm in diameter 
[24]. Therefore, from a more practical perspective, the deci-
sion of treating with adjuvant chemotherapy should be based 
on both clinical features and molecular findings during the 
course of the disease.
In pathological diagnosis, there is still confusion regarding 
whether all diffuse gliomas (diffuse astrocytomas and oligo-
dendrogliomas) need to be analyzed for 1p19q status to meet 
WHO diagnostic requirements. The 2016 Blue Book on CNS 
tumors [4] states that the presence of an astrocytic “compo-
nent” is compatible with the diagnosis of oligodendroglioma 
if it shows 1p19q codeletion and IDH mutation. This implies 
that only oligodendrogliomas and mixed oligodendroglio-
ma-astrocytoma tumors need to be analyzed for 1p19q code-
letion, whereas histologically pure astrocytomas do not. On 
the other hand, according to the 2016 CNS WHO review ar-
ticle published in Acta Neuropathologica [3], a diffuse glioma 
that is histologically astrocytic but has 1p19q codeletion and 
IDH mutation necessitates a diagnosis of oligodendroglioma. 
This implies that 1p19q analysis is required for all cases of 
IDH-mutated diffuse glioma, including pure astrocytic tu-
mors. Neuropathologists who are experts in practice have 
clarified that diffuse gliomas with IDH mutation and astro-
cytoma morphology do not need reflex testing for 1p19q 
loss. They can be designated as astrocytoma, IDH-mutant if 
ATRX and p53 immunohistochemistry findings support the 
diagnosis [25]. 
In terms of radiological assessment for low grade gliomas, 
there are something difficulties to apply it in clinical fields 
because low grade gliomas are usually measured in T2/
FLAIR rather than contrast enhancement as these tumors 
rarely enhance. In addition, as responses to treatment are of-
ten relatively modest, minor response criteria that are char-
acterized by a decrease in T2/FLAIR tumor of 25% to 50% 
was introduced. Although T2/FLAIR provides the clearest 
and the most reproducible definition of low-grade gliomas, 
distinguishing tumor from radiation-induced changes, post-
surgical changes, demyelination, ischemic injury, and other 
comorbid events can be difficult. As validated imaging mo-
dalities that can more accurately reflect tumor burden are 
developed, these criteria can be revised. For low grade glio-
mas, clinical outcome assessments such as neurocognitive 
function, quality of life, and seizure control play important 
roles in determining the response to treatment. The RANO 
group has recently proposed guidelines for using seizure 
control as a metric to assess the efficacy of tumor treatment 
in clinical trials for low grade gliomas by using a composite 
score of seizure classification, frequency, outcome, and sever-
ity [26]. Another challenge in determining response and 
progression of WHO grade II gliomas is the difficulty in ac-
curately measuring the tumor using only two-dimension. 
There is ongoing work to determine if measuring T2/FLAIR 
volume is more accurate in determining changes in tumor 
burden and whether newer approaches such as determining 
changes in tumor volume growth trajectory can be more reli-
able and sensitive measure of response [27].
Limitations of this KSNO guideline for WHO grade II ce-
rebral gliomas are not different from those of the KSNO 
guideline for other brain tumors such as WHO grade III and 
IV. The major weakness of this guideline is limited application 
to Korean patients with WHO grade II gliomas due to unique 
medical atmosphere of Korea. Therefore, it is less helpful for 
physicians treating patients outside of Korea. To use this 
guideline globally, Asian countries including Japan and China 
should have a comprehensive network for brain tumor man-
agement. They should cooperate and share their guidelines. 
Further, it will be helpful for Asian countries to establish a 
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global guideline that is commonly applicable to these coun-
tries. The next hurdle to be overcome is molecular and genetic 
test for WHO grade II gliomas and whole brain tumors. Ge-
netic information is now rapidly changing, making it difficult 
to establish definite guideline for clinical practice. The cIM-
PACT-NOW is a notable example that shows rapid change in 
molecular diagnosis of brain tumors [9,28,29]. Third, this 
guideline does not include medical management. In clinical 
practice, physicians are still struggling to manage the mass ef-
fect, brain edema, radiation necrosis, seizures, endocrine dys-
functions, fatigues, psychological disorders such as depression 
and anxiety, and venous thromboembolism [17]. However, 
there is no consensus for steroid therapy, the use of antiepi-
leptic drugs, or antipsychotic drugs for these patients. Finally, 
this guideline did not include all WHO grade II cerebral glio-
mas. Only patients with diffuse astrocytoma and oligoden-
droglioma were subjects for this guideline. Other WHO grade 
II cerebral gliomas such as ependymoma, pilomyxoid astro-
cytoma, and pleomorphic xanthoastrocytoma were not in-
cluded in this guideline, neither gliomas of the spinal cord. 
Therefore, the KSNO’s Guideline Working Group has plans to 
continue the process of updating guidelines so that limitations 
of this version can be improved.
CONCLUSIONS
There was no practical guideline for the management of 
brain tumor patients. Thus, the KSNO developed this guideline 
that could be used by physicians under unique medical circum-
stances in Korea. The KSNO Guideline Working Group com-
posed of 35 multidisciplinary medical experts in Korea pre-
pared “The KSNO guideline for WHO grade II cerebral glioma 
in adults: Version 2019.01” as the third guideline following the 
KSNO Guideline for WHO grade IV and III glioma. 
In summary, WHO grade II gliomas in the brain should 
be treated by maximal safe resection if feasible, followed by 
radiotherapy and/or chemotherapy according to individual 
molecular and histopathological features of tumors as well as 
clinical status of patients. As data emerging in the past few 
years have led to significant changes in the diagnosis, catego-
rization, and treatment of WHO grade II gliomas, we plan to 
update this guideline consistently. Consecutive guideline for 
other brain tumors such as WHO grade I gliomas, brain me-
tastasis, and meningiomas will also be published by the 
KSNO Guideline Working Group.
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